Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Urologic Oncology|May 5, 2019
Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter studyAndrea Necchi, Salvatore Lo Vullo, Luigi Mariani, et al.
Clinical Genitourinary Cancer|March 2, 2015
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral CenterAndrea Necchi, Elena Farè, Salvatore Lo Vullo, et al.
European Urology Oncology|July 2, 2020
The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder CancerMarco Bandini, Giuseppina Calareso, Daniele Raggi, et al.
Immunotherapy|November 17, 2021
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, et al.
European Urology|January 6, 2024
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder CancerFilippo Pederzoli, Michela Riba, Chiara Venegoni, et al.
Investigational New Drugs|February 14, 2016
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancerAndrea Necchi, Salvatore Lo Vullo, Luigi Mariani, et al.
World Journal of Urology|September 20, 2022
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?Giuseppe Fallara, Alessandro Larcher, Giuseppe Rosiello, et al.
World Journal of Urology|May 6, 2023
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomyGiuseppe Rosiello, Pietro Scilipoti, Alessandro Larcher, et al.
World Journal of Urology|April 27, 2024
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombusPietro Scilipoti, Giuseppe Rosiello, Alessandro Larcher, et al.
BJU International|September 19, 2017
First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 studyAndrea Necchi, Salvatore Lo Vullo, Federica Perrone, et al.
Pageof 13